论文部分内容阅读
目的探讨分析依达拉奉联合尿激酶溶栓治疗急性脑梗死的临床疗效。方法回顾性分析2010年7月到2012年7月间在我院进行超早期溶栓治疗的60例急性脑梗死患者的临床资料。结果经过两周的治疗后,治疗组总有效率为93.33%,显著高于对照组的73.33%,具有统计学意义(P<0.05);治疗组的NIHSS评分明显低于对照组,具有显著性差异(P<0.05)。结论依达拉奉联合尿激酶溶栓治疗急性脑梗死的临床疗效显著,值得在基层医院推广。
Objective To investigate the clinical efficacy of edaravone combined with urokinase thrombolysis in the treatment of acute cerebral infarction. Methods The clinical data of 60 patients with acute cerebral infarction who underwent ultra-early thrombolysis in our hospital from July 2010 to July 2012 were retrospectively analyzed. Results After two weeks of treatment, the total effective rate of the treatment group was 93.33%, which was significantly higher than that of the control group (73.33%, P <0.05). The NIHSS score of the treatment group was significantly lower than that of the control group Difference (P <0.05). Conclusion Edaravone combined with urokinase thrombolysis in the treatment of acute cerebral infarction clinical efficacy is significant, it is worth to promote in primary hospitals.